In a major step toward strengthening international regulatory cooperation, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) have announced a new liaison programme designed to deepen collaboration between the two agencies. The initiative was unveiled during the DIA Global Annual Meeting in Philadelphia by MHRA Chief Executive Lawrence Tallon and FDA Deputy Commissioner Grace Graham.
The programme will establish dedicated liaison officers within both organizations, creating direct channels for daily communication, scientific exchange, and coordinated responses to emerging regulatory challenges. The move is expected to strengthen cooperation across medicines, medical devices, and rapidly evolving technologies such as artificial intelligence.
According to the agencies, the new arrangement aims to improve the sharing of regulatory expertise and facilitate faster discussions on complex scientific and regulatory issues. By enhancing information exchange, both regulators hope to respond more effectively to advances in healthcare innovation while ensuring patient safety remains the top priority.
The liaison programme builds upon a long-standing relationship between the MHRA and FDA, which has already expanded in recent years through joint efforts involving medical device regulation, AI governance, and international regulatory harmonization. Earlier collaborations focused on reducing duplication in regulatory processes and improving patient access to innovative health technologies.
Both agencies emphasized that the initiative does not affect their regulatory independence. While collaboration and alignment will increase in areas of mutual interest, the MHRA and FDA will continue to make their own independent regulatory decisions in accordance with their respective legal frameworks.
As healthcare technologies become increasingly global, the MHRA-FDA liaison programme represents a significant milestone in regulatory cooperation, with the potential to influence future international approaches to medicines and medical device oversight.
